Testicular-cancer survivors experience compromised language following chemotherapy: Findings in a Swedish population-based study 326 years after treatment

Acta Oncologica

Volumn 51, Issue 2, 2012, Pages 185-197

  Skoogh, Johanna ^a   Steineck, Gunnar ^a,b   Stierner, Ulrika ^c   Cavallin Ståhl, Eva ^d   Wilderäng, Ulrica ^a   Wallin, Anders ^a   Gatz, Margaret ^b,e   Johansson, Boo ^f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; HUMAN; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; TESTIS CANCER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EDUCATIONAL STATUS; FOLLOW-UP STUDIES; HUMANS; LANGUAGE DISORDERS; MALE; MIDDLE AGED; RISK; SURVIVORS; SWEDEN; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856474213     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.602113     Document Type: Article

References (39)

1. Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Stahl O, Klepp O, et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: A report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol Epub 2011 Apr 11.
2. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008;299: 672-84.
3. Hefl in LH, Meyerowitz BE, Hall P, Lichtenstein P, Johansson B, Pedersen NL, et al. Cancer as a risk factor for long-term cognitive defi cits and dementia. J Natl Cancer Inst 2005;97:854-6.
4. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for highrisk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-8.
5. Castellon S, Ganz PA. Neuropsychological studies in breast cancer: In search of chemobrain. Breast Cancer Res Treat 2009;116:125-7.
6. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. J Clin Oncol 2004;22:2233-9.
7. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. J Clin Oncol 2007;25:2455-63.
8. Vardy J, Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007;63:183-202.
9. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med 1999;340: 1383-9.
10. Kreicbergs U, Valdimarsdottir U, Onelov E, Henter JI, Steineck G. Talking about death with children who have severe malignant disease. N Engl J Med 2004;351:1175-86.
11. Steineck G, Bergmark K, Henningsohn L, al-Abany M, Dickman PW, Helgason A. Symptom documentation in cancer survivors as a basis for therapy modifi cations. Acta Oncol 2002;41:244-52.
12. Steineck G, Hunt H, Adolfsson J. A hierarchical step-model for causation of bias-evaluating cancer treatment with epidemiological methods. Acta Oncol 2006;45:421-9.
13. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
14. S koogh J, Steineck G, Cavallin-Stahl E, Wilderang U, Hakansson UK, Johansson B, et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: A population-based long-term follow-up of testicular cancer survivors. Int J Androl 2011;34:183-92.
15. Skoogh J, Ylitalo N, Larsson Omerov P, Hauksdottir A, Nyberg U, Wilderang U, et al. 'A no means no' -measuring depression using a single-item question versus Hospital Anxiety and Depression Scale (HADS-D). Ann Oncol 2010; 21:1905 - 9.
16. Fossa SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, et al. Quality of life in good prognosis patients with metastatic germ cell cancer: A prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/ TE20). J Clin Oncol 2003;21:1107-18.
17. Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, von der Maase H. Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 2009;15:296-301.
18. Schagen SB, Boogerd W, Muller MJ, Huinink WT, Moonen L, Meinhardt W, et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 2008;47:63-70.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A qualityof- life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
20. Downie FP, Mar Fan HG, Houede-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psychooncology 2006;15:921-30.
21. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006;20:76-89.
22. Valenzuela MJ, Sachdev P. Brain reserve and cognitive decline: A non-parametric systematic review. Psychol Med 2006;36:1065-73.
23. White L, Katzman R, Losonczy K, Salive M, Wallace R, Berkman L, et al. Association of education with incidence of cognitive impairment in three established populations for epidemiologic studies of the elderly. J Clin Epidemiol 1994;47:363-74.
24. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: Variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 2008;65: 1467-71.
25. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448-60.
26. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355:1075-6.
27. Troy L, McFarland K, Littman-Power S, Kelly BJ, Walpole ET, Wyld D, et al. Cisplatin-based therapy: A neurological and neuropsychological review. Psychooncology 2000;9:29-39.
28. Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 2007;19:108-14.
29. Alici-Evcimen Y, Breitbart WS. Ifosfamide neuropsychiatric toxicity in patients with cancer. Psychooncology 2007;16: 956-60.
30. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005; 28:277-80.
31. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001; 91:1297-303.
32. Thilers PP, Macdonald SW, Herlitz A. The association between endogenous free testosterone and cognitive performance: A population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 2006;31:565-76.
33. Travison TG, Araujo AB, Beck TJ, Williams RE, Clark RV, Leder BZ, et al. Relation between serum testosterone, serum estradiol, sex hormone-binding globulin, and geometric measures of adult male proximal femur strength. J Clin Endocrinol Metab Epub 2008 Dec 23.
34. Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer 1996; 74:1674-9.
35. Green HJ, Pakenham KI, Gardiner R. Cognitive defi cits associated with cancer: A model of subjective and objective outcome. Psychol Health Med 2005;10:145-60.
36. Ownsworth TL, McFarland K. Memory remediation in long-term acquired brain injury: Two approaches in diary training. Brain Inj 1999;13:605-26.
37. Smith PC, Kendall LM. Retranslation of expectations: An approach to the construction of unambiguous anchors for rating scales. J Appl Psychol 1963;47:149-55.
38. Cicerone KD, Dahlberg C, Kalmar K, Langenbahn DM, Malec JF, Bergquist TF, et al. Evidence-based cognitive rehabilitation: Recommendations for clinical practice. Arch Phys Med Rehabil 2000;81:1596-615.
39. Cicerone KD, Dahlberg C, Malec JF, Langenbahn DM, Felicetti T, Kneipp S, et al. Evidence-based cognitive ehabilitation: Updated review of the literature from 1998 through 2002. Arch Phys Med Rehabil 2005;86: 1681-92.